IMTERO: Effect of Management of the Endometrioma on Ovarian Reserve
Study Details
Study Description
Brief Summary
Investigators aimed at comparing the impact on ovarian reserve of three usual-care management options of endometrioma, laparoscopic cystectomy (LC), hormonal treatment with daily dienogest (HT), or mere ultrasound control (UC).
Ovarian reserve will be measured by the effect on the circulating levels of anti-Mullerian hormone (AMH). Secondary objectives will be effect on pelvic pain, other symptoms, sexual function, quality of life, progression in size of the endometrioma, impact on work productivity and activity impairment, and satisfaction with treatment.
Participants will be followed by up to one year.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Investigators aimed at comparing the impact on ovarian reserve of three usual-care management options of endometrioma, laparoscopic cystectomy (LC), hormonal treatment with daily dienogest (HT), or mere ultrasound control (UC).
Secondary objectives were the comparison of the effect on i) pelvic pain, including dysmenorrhea, non-menstrual pelvic pain, deep dyspareunia, or dyschezia, ii) other symptoms including menorrhagia, gastrointestinal symptoms different to dyschezia, or urinary symptoms;
- quality of life as assessed by the EHP-30 questionnaire; iv) sexual functions, as assessed the female sexual function index (FSFI); v) progression in the size of the tumor in the case of the two non-surgical approaches; vi) impact on work productivity and activity impairment; vii) satisfaction in the patient.
A prospective assessment will be performed on a cohort of women with endometrioma diagnosed by ultrasound from diagnosis for up to one year. The assignment to each management option will be performed under usual care conditions so that the selected option will result from the shared clinical decision of the clinician with the patient.
The target population will be composed of Caucasian premenopausal women between 18-39 years with the diagnosis of endometrioma, one or more, with a diameter of up to 7 cm by endovaginal ultrasound. Body mass index comprised between 17-30 Kg/m2.
Participants will be controlled at 3 months, 6 months and one year.
Study Design
Outcome Measures
Primary Outcome Measures
- Change in the levels of anti-Mullerian hormone [Change from baseline AMH levels at 1 year]
Ovarian reserve as measured by the levels of AMH
Secondary Outcome Measures
- Change of Pelvic pain [Change from baseline pelvic pain at 1 year.]
Dysmenorrhea, non-menstrual pelvic pain, deep dyspareunia, or dyschezia measured by a visual analogue scale from 0 to 5 and in which higher score means worse outcome.
- Change in quality of life [Change from baseline EHP-30 score at 1 year.]
Assessed by the Endometriosis Health Profile-30 (EHP-30) questionnaire, in which the minimum score is 0 and the highest 150. Higher score means a worse outcome.
- Change in sexual function [Change from baseline FSFI score at 1 year.]
Assessed the female sexual function index (FSFI) questionnaire in which there are 6 questions from 0 to 5. The highest score is 30 and the lowest 0. Lower score means worse outcome.
- Change in volume of the tumor [Change from baseline endometrioma volume at 1 year.]
Measured by ultrasound, in the case of the two non-surgical approaches
- Satisfaction of the patient [Satisfaction level measured by Likert scale at 1 year.]
Satisfaction as assessed by a Likert scale in which the score is from 0 to 5 in which higher score means better outcome.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Caucasian premenopausal women between 18-39 years with the diagnosis of endometrioma, one or more, with a diameter of up to 7 cm by endovaginal ultrasound. Body mass index comprised between 17-30 Kg/m2
Exclusion Criteria:
-
Previous ovarian surgery;
-
Previous pathologies involving the ovary, including other ovarian tumors, polycystic ovaries, or pelvic inflammatory disease;
-
Previous diagnosis of cancer treated with chemotherapy or local radiotherapy;
-
Diseases affecting the endocrine system, diabetes, thyroid, hyperprolactinemia, or the immune system (lupus, Crohn,…);
-
Genesic wish;
-
Endometrioma >7 cm;
-
Unhealthy habits, including smoking, alcohol consumption above social level, or illicit drugs;
-
Insufficient level of autonomy for unrestrictedly signing informed consent;
-
Current or previous use of hormonal contraceptives, Gonadotropin-Releasing Hormone (GnRH) analogues, any drug with a known effect on endometriosis, or any drug under investigation, for what a washing up period of 6 months will be required in all cases.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hosp Clinico Universitario-INCLIVA | Valencia | Spain | 46010 |
Sponsors and Collaborators
- University of Valencia
- Hospital Comarcal Francesc de Borja Gandía, Valencia, Spain
- Hospital Universitario San Juan de Alicante
- Poznan University of Medical Sciences
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IMTERO_22